ES2102986T3 - Utilizacion de un modulador de la fosforilacion de las proteinas como medicamento en el tratamiento de la amiloidosis asociada con la enfermedad de alzheimer. - Google Patents

Utilizacion de un modulador de la fosforilacion de las proteinas como medicamento en el tratamiento de la amiloidosis asociada con la enfermedad de alzheimer.

Info

Publication number
ES2102986T3
ES2102986T3 ES91107844T ES91107844T ES2102986T3 ES 2102986 T3 ES2102986 T3 ES 2102986T3 ES 91107844 T ES91107844 T ES 91107844T ES 91107844 T ES91107844 T ES 91107844T ES 2102986 T3 ES2102986 T3 ES 2102986T3
Authority
ES
Spain
Prior art keywords
modulator
treatment
phosphorilation
medication
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91107844T
Other languages
English (en)
Inventor
Joseph D Buxbaum
Samuel E Gandy
Paul Greengard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rockefeller University
Original Assignee
Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24088213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2102986(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rockefeller University filed Critical Rockefeller University
Application granted granted Critical
Publication of ES2102986T3 publication Critical patent/ES2102986T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

SE DESCRIBE EL USO DE AL MENOS UN MODULADOR DE QUINASA O UN MODULADOR DE FOSFATASA CAPAZ DE INCREMENTAR O REDUCIR LA VELOCIDAD DEL PROCESAMIENTO PROTEOLITICO DE LAS PROTEINAS QUE SE ENCUENTRAN EN LOS MODULOS NEUROFIBRILARES INTRACELULARES Y EN LAS PLACAS AMILOIDEAS EXTRACELULARES PARA LA PREPARACION DE UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE LA AMILOIDOSIS ASOCIADA A LA ENFERMEDAD DE ALZHEIMER, DONDE DICHA COMPOSICION FARMACEUTICA CONTIENE DICHO MODULADOR EN UNA CANTIDAD QUE REGULA EFICAZMENTE LA FOSFORILACION DE DICHAS PROTEINAS.
ES91107844T 1990-05-16 1991-05-15 Utilizacion de un modulador de la fosforilacion de las proteinas como medicamento en el tratamiento de la amiloidosis asociada con la enfermedad de alzheimer. Expired - Lifetime ES2102986T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52420290A 1990-05-16 1990-05-16

Publications (1)

Publication Number Publication Date
ES2102986T3 true ES2102986T3 (es) 1997-08-16

Family

ID=24088213

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91107844T Expired - Lifetime ES2102986T3 (es) 1990-05-16 1991-05-15 Utilizacion de un modulador de la fosforilacion de las proteinas como medicamento en el tratamiento de la amiloidosis asociada con la enfermedad de alzheimer.

Country Status (8)

Country Link
EP (1) EP0457295B1 (es)
JP (1) JPH0725786A (es)
AT (1) ATE151287T1 (es)
CA (1) CA2042668C (es)
DE (1) DE69125523T2 (es)
DK (1) DK0457295T3 (es)
ES (1) ES2102986T3 (es)
GR (1) GR3024032T3 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538983A (en) * 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5089517A (en) * 1990-08-03 1992-02-18 The Board Of Trustees Of The Leland Stanford Junior University Neuroprotection by indolactam v and derivatives thereof
EP0544942A1 (en) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel tools for the diagnosis and treatment of Alzheimer disease
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
ATE386115T1 (de) * 1991-12-06 2008-03-15 Max Planck Gesellschaft Verwendung von proteinkinasen zur diagnose und behandlung der alzheimer krankheit
EP0551200A1 (en) * 1992-01-07 1993-07-14 National University Of Singapore Protein phosphatase inhibitors for use in therapy
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
JP2893029B2 (ja) * 1992-08-10 1999-05-17 旭化成工業株式会社 心臓保護剤
JPH0680569A (ja) * 1992-09-03 1994-03-22 Asahi Chem Ind Co Ltd 血小板凝集阻害剤
WO1994009370A1 (en) 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors
US5962463A (en) * 1992-10-09 1999-10-05 Massachusetts Institute Of Technology Methods of stimulating non-amyloidogenic processing of the amyloid precursor protein
DK1060750T3 (da) * 1993-03-29 2006-01-09 Univ Kingston Propan-1,3-disulfonsyre og dens farmaceutisk acceptable salte til behandling af amyloidose
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
JPH08511005A (ja) * 1993-06-01 1996-11-19 コーテックス ファーマシューティカルズ インコーポレイテッド 神経疾患の治療におけるアルカリ性または酸性ホスファターゼインヒビター
IL110289A (en) * 1993-08-06 1998-01-04 Policlinico San Matteo Istitut Pharmaceutical preparations containing 4-iodo-4-deoxydoxorubicin for the treatment of amyloidosis
GB9325395D0 (en) * 1993-12-11 1994-02-16 Ciba Geigy Ag Compositions
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US6083920A (en) * 1995-12-21 2000-07-04 Ayurcore, Inc. Compositions for modulating intracellular inositol trisphosphate concentration
CA2279651A1 (en) * 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US7144997B2 (en) * 1997-07-24 2006-12-05 Curis, Inc. Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
WO1999016457A2 (en) * 1997-10-01 1999-04-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel composition for treating, preventing and/or delaying ischemic cell death
AU4990599A (en) * 1998-07-14 2000-02-07 Brigham And Women's Hospital Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US6399107B1 (en) 1998-12-22 2002-06-04 Alcon Laboratories, Inc. Use of inhibitors of gag synthesis for the treatment of corneal haze
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
DE10352450A1 (de) * 2003-11-07 2005-06-23 Ruprecht-Karls-Universität Heidelberg Neues Mittel zur prophylaktischen und/oder therapeutischen Behandlung von Morbus Alzheimer
US7790881B2 (en) 2004-09-23 2010-09-07 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC)
BRPI0519243A2 (pt) 2004-12-22 2009-01-06 Neurochem Int Ltd mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
US8372886B2 (en) 2005-12-22 2013-02-12 Kiacta Sarl Treatment of renal disorders, diabetic nephropathy and dyslipidemias
MY153198A (en) 2006-03-29 2015-01-29 Wista Lab Ltd Inhibitors of protein aggregation
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
EP3851447B1 (en) 2006-10-12 2023-09-06 Bellus Health Inc. Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
AU2011358840B2 (en) 2011-02-11 2017-05-04 TauRx Therapeutics Management Ltd Phenothiazine diaminium salts and their use
EP3347486A4 (en) * 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
US20220016073A1 (en) * 2017-11-15 2022-01-20 Korea Research Institute Of Bioscience And Biotechnology Composition for preventing or treating neurodegenerative diseases, containing diterpene-based compound
JP7037814B2 (ja) * 2018-03-28 2022-03-17 国立大学法人山口大学 ホルボールエステルを有効成分とする軸索の伸展剤
WO2023076936A1 (en) * 2021-10-26 2023-05-04 Robert Vito Farese Use of auranofin as an inhibitor of atypical protein kinase c for treatment of neurodegenerative disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085913B2 (ja) * 1985-09-12 1996-01-24 ザ・アドミニストレ−タ−ズ・オブ・ザ・ツ−レイン・エデユケイシヨナル・フアンド 治療用ソマトスタチン同族体

Also Published As

Publication number Publication date
EP0457295A2 (en) 1991-11-21
JPH0725786A (ja) 1995-01-27
ATE151287T1 (de) 1997-04-15
CA2042668A1 (en) 1991-11-17
EP0457295B1 (en) 1997-04-09
DK0457295T3 (da) 1997-04-28
DE69125523D1 (de) 1997-05-15
GR3024032T3 (en) 1997-10-31
DE69125523T2 (de) 1997-08-14
EP0457295A3 (en) 1992-08-05
CA2042668C (en) 2002-12-03

Similar Documents

Publication Publication Date Title
ES2102986T3 (es) Utilizacion de un modulador de la fosforilacion de las proteinas como medicamento en el tratamiento de la amiloidosis asociada con la enfermedad de alzheimer.
ATE308336T1 (de) Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
DE69200675D1 (de) Verwendung von Droloxifen bei der Behandlung von Knochenerkrankungen.
DK549189D0 (da) Galanthamin-analoge samt anvendelse af disse til fremstilling af laegemidler til behandling af alzheimer's syge
EE05492B1 (et) Farmatseutilised kompositsioonid, nendega seotud meetodid ja nende kasutamine amloidogeensete haiguste korral
ATE206919T1 (de) Verwendung des wirkstoffs flupirtin zur herstellung eines arzneimittels zur bekämpfung von muskelverspannungen
ATE157251T1 (de) Verwendung von inositoltriphosphat zur behandlung von entzündungen
EP1040830A4 (en) REMEDY FOR NEURODEGENERATIVE DISEASES
ATE431364T1 (de) Inhibitoren der menschlichen elastase von neutrophilen
ES2119185T3 (es) Tratamiento de enfermedades micobacterianas por administracion de productos de la proteina bactericida/que aumenta la permeabilidad.
ATE104855T1 (de) Verwendung von inositoltrisphosphat zur herstellung eines arzneimittels gegen knochenerkrakungen.
YU49215B (sh) Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
FI810380L (fi) Fenylpiperazinderivat av 1,3,4-oxadiazolylfenoler deras framstaellning och dessa innehaollande terapeutiska aemnen
DE69121964D1 (de) Wachstumsinhibierender Faktor und für den wachstumsinhibierenden Faktor kodierender cDNS
ATE229336T1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
DE69124415D1 (de) Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
ATE201993T1 (de) Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie
ATE6124T1 (de) Arzneimittel zur lokalen behandlung des glaukoms.
DE3772047D1 (de) Pyrazin zur behandlung von haemodynamischen und metabolischen krankheiten.
DE69203098D1 (de) Verwendung eines Polypeptids mit humaner Interleukin-2 Aktivität zur Herstellung pharmazeutischer Zusammensetzungen zur Behandlung von Pneumothoraxen.
FR2648042B1 (fr) Utilisation de phenylethanolaminotetralines pour la preparation de medicaments pour le traitement des affections oculaires
FR2661831B1 (fr) Formules pharmaceutiques pour le traitement des maladies vasculaires peripheriques.
FR2656529B3 (fr) Composition therapeutique destinee au traitement des troubles oculaires de l'accomodation.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 457295

Country of ref document: ES